Effects of orally administered undenatured type II collagen against arthritic inflammatory diseases: A mechanistic exploration

International Journal of Clinical Pharmacology Research

Volumn 22, Issue 3-4, 2002, Pages 101-110

  Bagchi, D ^b   Misner, B ^c   Bagchi, M ^c   Kothari, S C ^c   Downs, B W ^c   Fafard, R D ^c   Preuss, H G ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; AUTOANTIGEN; COLLAGEN TYPE 2; EPITOPE; GLYCOPROTEIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTHRALGIA; ARTHRITIS; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DUODENUM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOLOGICAL TOLERANCE; INFLAMMATORY DISEASE; INTESTINE LYMPHATIC TISSUE; JOINT FUNCTION; JOINT STIFFNESS; KILLER CELL; OPEN STUDY; OSTEOARTHRITIS; PEYER PATCH; PILOT STUDY; PROTEIN DENATURATION; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

ADMINISTRATION, ORAL; AGED; ARTHRITIS; ARTHRITIS, RHEUMATOID; COLLAGEN TYPE II; FEMALE; HUMANS; MIDDLE AGED; OSTEOARTHRITIS; PAIN MEASUREMENT; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 0038715418     PISSN: 02511649     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Trentham D.E., Halpner A.D., Trentham R.E., et al. Use of undenatured type II collagen in the treatment of rheumatoid arthritis. Clin. Prac. Alter. Med., 2, 254, 2001.
2. Helmick C.G., Lawrence R.C., Pollard R.A., et al. Arthritis and other rheumatic conditions: Who is affected now, will be affected later? Arthritis Care Res., 8, 203, 1995.
3. Trentham D.E., Dynesius-Trentham R.A., Orav E.J., et al. Effects of oral administration of type II collagen on rheumatoid arthritis. Science, 261, 1727, 1993.
4. Barnett M.L., Combitchi D., Trentham D.E. A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum., 39, 623, 1996.
5. Barnett M.L., Kremer J.M., St Clair E.W., et al. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum., 41, 290, 1998.
6. Nagler-Anderson C., Bober L.A., Robinson M.E., et al. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc. Natl. Acad. Sci., 83, 7443, 1986.
7. Benoist C., Mathis D. A revival of the B cell paradigm for rheumatoid arthritis pathogenesis? Arthritis Res., 2, 90, 2000.
8. Weyand C.M., Brandes J.C., Schmidt D., et al. Functional properties of CD4+ CD28- T cells in the aging immune system. Mech. Ageing Dev., 102, 131, 1998.
9. Mowat M.A. The regulation of immune responses to dietary protein antigens. Immunol. Today, 8, 93, 1987.
10. Weiner H.L. Oral tolerance: Immune mechanisms and treatment of autoimmune diseases. Immunol. Today, 18, 335, 1997.
11. Rudd, P.M., Elliott T., Cresswell P., et al. Glycosylation and the immune system. Science, 291, 2370, 2001.
12. Parekh R.B., Dwek R.A., Sutton B.J., et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in glycosylation pattern of total serum IgG. Nature, 316, 452, 1985.
13. Youings A., Chang S., Dwek R.A., et al. Site-specific glycosylation of human immunoglobulin G is altered in four rheumatoid arthritis patients. Biochem. J., 314, 621, 1996.
14. McCoy J.P., Chambers W.H. Carbohydrates in functions of natural killer cells. Glycobiology, 1, 321, 1991.
15. Tsuchiya N., Endo T., Matsuta K., et al. Detection of glycosylation abnormality in rheumatoid IgG using N-acetylglucosamine-specific Psathyrella velutina lectin. J. Immunol., 151, 1137, 1993.
16. Tsuchiya N., Endo T., Shiota M., et al. Distribution of glycosylation abnormality among serum IgG subclasses from patients with rheumatoid arthritis. Clin. Immunol. Immunopathol., 70, 47, 1994.
17. Rademacher T.W., Williams P., Dwek R.A. Agalactosyl glycoforms of IgG autoantibodies are pathogenic. Proc. Natl. Acad. Sci., 91, 6123, 1994.
18. Tsuchiya N., Endo T., Matsuta K., et al. Effects of galactose depletion from oligosaccharide chains on immunological activities of human IgG. J. Rheumatol., 16, 285, 1989.
19. Watson M., Rudd P.M., Bland M., et al. Sugar printing rheumatic diseases: A potential method for disease differentiation using immunoglobulin G oligosaccharides. Arthritis Rheum., 42, 1682, 1999.
20. Lang G.A., Yeaman G.R. Autoantibodies in endometrioses sera recognize a Thomsen-Friedenreich-like carbohydrate antigen. J. Autoimmun., 16, 151, 2001.
21. Corthay A., Backlund J., Broddefalk J., et al. Epitope glycosylation plays a critical role for T cell recognition of type II collagen in collagen-induced arthritis. Eur. J. Immunol., 28, 2580, 1998.
22. Sieper J., Kary S., Sorensen H. Oral type II collagen treatment in early rheumatoid arthritis. Athritis Rheum., 39, 41, 1996.
23. Burkhardt H., Koller T, Engstrom A., et al. Epitope-specific recognition of type II collagen by rheumatoid arthritis antibodies is shared with recognition by antibodies that are arthritogenic in collagen-induced arthritis in the mouse. Arthritis. Rheum., 46, 2339, 2002.
24. Fujii K., Tsuji M., Murota K. An improved enzyme-linked immunosorbent assay of anti-collagen antibodies in human serum. J. Immunol. Methods, 124, 63, 1989.
25. Williams P.J., Rademacher T.W. Analysis of murine IgG isotype galactosylation in collagen-induced arthritis. Scand. J. Immunol., 44, 381, 1996.
26. Terato K., Hasty K.A., Reife R.A. Induction of arthritis with monoclonal antibodies to collagen. J. Immunol., 146, 2103, 1992.
27. Ryle A.P. The porcine pepsin and pepsinogens. In: Perlmann G.E., Lerand L. (Eds.). "Methods in Enzymology." Vol. XIX, Academic Press, New York, 1970, p. 316.
28. Miller E.J., Matukas VJ. Chick cartilage collagen: A new type of alpha 1 chain not present in bone or skin of the species. Proc. Natl. Acad. Sci., 64, 1264, 1969.
29. Trelstad R.L., Kang A.H., Igarashi S. Isolation of two distinct collagens from chick cartilage. Biochem., 9, 4993, 1970.
30. Herbage D., Bouillet J., Bernengo J.C. Biochemical and physiochemical characterization of pepsin-solubilized type II collagen from bovine articular cartilage. Biochem. J. 161, 303, 1977.
31. Ortolani F., Giordano M., Marchini M. A model for type II collagen fibrils: Distinctive D-band patterns in native and reconstituted fibrils compared with sequence data for helix and telopeptide domains. Biopolymers., 54, 448, 2000.
32. Meyer O. Oral immunomodulation therapy in rheumatoid arthritis. Joint Bone Spine., 67, 384, 2000.
33. Kim W.U., Lee W.K., Ryoo J.W. Suppression of collagen-induced arthritis by single administration of poly(lactic-co-glycolic acid) nanoparticles entrapping type II collagen: A novel treatment strategy for induction of tolerance. Arthritis Rheum., 46, 1109, 2002.
34. Schulte S., Unger C., Mo J.A. Arthritis-related B cell epitopes in collagen II are conformation-dependent and sterically privileged in accessible sites of cartilage collagen fibrils. J. Biol. Chem., 273, 1551, 1998.
35. Backlund J., Carlsen S., Hoger T. Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritis. Proc. Natl. Acad. Sci., 99, 9960, 2002.
36. Matteson E.L. Current treatment strategies for rheumatoid arthritis. Mayo Clin. Proc., 75, 69, 2000.